Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Avidity Biosciences Inc (NASDAQ: RNA) closed at $44.18 up 2.74% from its previous closing price of $43.0. In other words, the price has increased by $2.74 from its previous closing price. On the day, 1.27 million shares were traded. RNA stock price reached its highest trading level at $44.19 during the session, while it also had its lowest trading level at $43.15.
Ratios:
For a deeper understanding of Avidity Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.26 and its Current Ratio is at 9.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Roth Capital on September 17, 2025, initiated with a Buy rating and assigned the stock a target price of $62.
On June 24, 2025, Bernstein started tracking the stock assigning a Outperform rating and target price of $50.Bernstein initiated its Outperform rating on June 24, 2025, with a $50 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 22 ’25 when Hughes Steven George sold 2,208 shares for $40.58 per share. The transaction valued at 89,601 led to the insider holds 38,867 shares of the business.
McCarthy Teresa sold 15,000 shares of RNA for $621,142 on Sep 15 ’25. The Chief Human Resources Officer now owns 97,130 shares after completing the transaction at $41.41 per share. On Sep 15 ’25, another insider, Hughes Steven George, who serves as the Chief Medical Officer of the company, sold 1,542 shares for $45.41 each. As a result, the insider received 70,022 and left with 38,867 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 6446009856 and an Enterprise Value of 4505895424. For the stock, the TTM Price-to-Sale (P/S) ratio is 600.75 while its Price-to-Book (P/B) ratio in mrq is 4.47. Its current Enterprise Value per Revenue stands at 419.973 whereas that against EBITDA is -8.686.
Stock Price History:
The Beta on a monthly basis for RNA is 0.93, which has changed by -0.06596196 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 1.93%, while the 200-Day Moving Average is calculated to be 30.60%.
Shares Statistics:
For the past three months, RNA has traded an average of 3.35M shares per day and 2399200 over the past ten days. A total of 145.90M shares are outstanding, with a floating share count of 131.53M. Insiders hold about 9.85% of the company’s shares, while institutions hold 90.98% stake in the company. Shares short for RNA as of 1757894400 were 22242546 with a Short Ratio of 6.64, compared to 1755216000 on 15671917. Therefore, it implies a Short% of Shares Outstanding of 22242546 and a Short% of Float of 15.359998999999998.
Earnings Estimates
The dynamic stock of Avidity Biosciences Inc (RNA) is currently being evaluated by a team of 15.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$1.27, with high estimates of -$0.61 and low estimates of -$2.36.
Analysts are recommending an EPS of between -$3.33 and -$6.26 for the fiscal current year, implying an average EPS of -$4.49. EPS for the following year is -$4.97, with 16.0 analysts recommending between -$3.24 and -$7.31.
